Carrasco 2001.

Methods	Study design: parallel RCT Study duration: not reported Follow‐up period: 3 months
Participants	Country: Spain Setting: multicentre (4 sites) Prevalent adult CAPD patients Number: treatment group (20); control group (11) Age, range (years): treatment group (58.8, 23 to 76); control group (56.7, 34 to 79) Sex (M/F): treatment group (9/11); control group (5/6) Exclusion criteria: antibiotics during the previous 30 days; serious illnesses (e.g. requiring hospitalisation during the previous 30 days); HIV positive; pregnancy or lactating; bicarbonate supplementation into PD fluids or orally
Interventions	Treatment group 25 mmol/L bicarbonate/15 mmol/L lactate PD solution Control group Standard 35 mmol/L lactate PD solution
Outcomes	Venous plasma bicarbonate concentrations Vital signs
Notes	This was a study primarily examining the ability of the new bicarbonate/lactate PD solutions on improving acidosis in PD patients Author contacted, awaiting response Funding received from Baxter Healthcare Ltd
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Block randomisation (3 patients/block)
Allocation concealment (selection bias)	Unclear risk	Insufficient information to permit judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Open label, however, unlikely to have affected measured outcomes
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to permit judgement
Incomplete outcome data (attrition bias) All outcomes	Low risk	No drop‐outs
Selective reporting (reporting bias)	High risk	Limited reporting of clinical outcomes
Other bias	Unclear risk	Insufficient information to permit judgement